-transparent.png){kind=logo}
Twenty patients with chronic myelogenous leukemia in terminal transformation were treated with regimen incorporating vindesine, prednisolone and additional cytosine arabinoside. Of the 19 patients in blastic crisis, complete remission was achieved in 13 (68.4%). All four patients with lymphoid morphology, and nine of the eleven patients with myeloid morphology, achieved complete remission (81.8%); the four with monocytoid morphology did not. One patient in accelerated phase also attained complete remission. The present results indicate that the regimen incorporating vindesine-cytosine arabinoside-prednisolone should be treatment of choice in CML-BC with lymphoid morphology and myeloid morphology as well.
Y Uzuka, and
Y Saito, and
H Takahash, and
M Komatsu
June 1987,
Seminars in oncology,
Y Uzuka, and
Y Saito, and
H Takahash, and
M Komatsu
December 1975,
Cancer,
Y Uzuka, and
Y Saito, and
H Takahash, and
M Komatsu
December 1988,
American journal of clinical oncology,
Y Uzuka, and
Y Saito, and
H Takahash, and
M Komatsu
July 1981,
Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
Y Uzuka, and
Y Saito, and
H Takahash, and
M Komatsu
October 1972,
Cancer,
Y Uzuka, and
Y Saito, and
H Takahash, and
M Komatsu
January 1991,
Haematologica,
Y Uzuka, and
Y Saito, and
H Takahash, and
M Komatsu
August 1988,
Cancer,
Y Uzuka, and
Y Saito, and
H Takahash, and
M Komatsu
July 1986,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Y Uzuka, and
Y Saito, and
H Takahash, and
M Komatsu
January 1984,
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Y Uzuka, and
Y Saito, and
H Takahash, and
M Komatsu
June 1975,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
